TYME News and Press, Tyme Technologies Inc. From 05/25/22

BEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fourth fiscal quarter and full y...

BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its Board of Directors has decided to explore potential str...

– Industry veteran, Christine D. Baker, joins Board of Directors – Douglas A. Michels appointed Chairman of the Board TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based ther...

-- Preclinical results from Georgetown University support that SM-88 is potentially a novel anti-cancer agent in drug resistant estrogen receptor positive breast cancer -- -- Poster presentation April 11, 1:30pm ET; abstract available online -- BEDMINSTER, N.J....

Tyme Technologies, Inc. (TYME) Q3 2022 Earnings Conference Call February 11, 2022, 08:30 AM ET Company Participants Lisa Wilson - Investor Relations Richie Cunningham - Chief Executive Officer Frank Porfido - Chief Financial Officer Yan Von Tornaut - Acting Chief Medical Officer Jonathan Ecka...

Tyme Technologies press release (NASDAQ:TYME): FQ3 GAAP EPS of -$0.03. The company is on track for mid-2022 full enrollment of HopES trial for SM-88 used in patients with high-risk Ewing’s and other sarcoma types. For further details see: Tyme Technologies GAAP EPS of -$0.03

– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – On track ...

AB, APO, ARES, AXL, BRKR, CAE, CLF, COOP, D, ENB, ESNT, FTS, G, GP, GPRE, GT, IAA, MGA, NBIX, NMRK, NWL, PRLB, TYME, UA, UAA, WPC For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Friday's open

TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday, ...

-- SM-88 with MPS arm of Phase 2/3 platform trial in metastatic pancreatic cancer discontinued for futility on primary endpoint of overall survival – TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer meta...